Literature DB >> 24458547

Determination of mazindol in human oral fluid by high performance liquid chromatography-electrospray ionization mass spectrometry.

Marcella Herbstrith de Oliveira1, Graciela Carlos, Ana Maria Bergold, Flavio Pechansky, Renata Pereira Limberger, Pedro Eduardo Fröehlich.   

Abstract

Brazil is one of the countries most affected by abuse of stimulant medications by professional drivers, especially fenproporex, amfepramone and mazindol. Even though their sale is banned, they can be found in illegal markets, such as those located on the country's borders. The use of oral fluid to monitor drug levels has many advantages over plasma and urine because it is noninvasive, easier to collect and more difficult to adulterate. The aim of this study was to develop and validate a sensitive and specific method to quantify mazindol in human oral fluid by liquid chromatography-mass spectrometry (LC-MS). The LC system consisted of an LC-MS system operated in selected ion monitoring mode. The mobile phase was composed of water at pH 4.0, acetonitrile and methanol (60:15:25 v/v/v) at a flow rate of 1.0 mL/min and propranolol was used as internal standard. Total running time was 10 min. The lower limit of quantification was 0.2 ng/mL and the method exhibited good linearity within the 0.2-20 ng/mL range (r = 0.9987). A rapid, specific, sensitive, linear, precise and accurate method was developed for determination of mazindol in human oral fluid according to European Medicines Agency guidelines, and is suitable for monitoring mazindol levels in oral fluid of professional drivers.
Copyright © 2014 John Wiley & Sons, Ltd.

Entities:  

Keywords:  mazindol; oral fluid; professional drivers; stimulants; validation

Mesh:

Substances:

Year:  2014        PMID: 24458547     DOI: 10.1002/bmc.3120

Source DB:  PubMed          Journal:  Biomed Chromatogr        ISSN: 0269-3879            Impact factor:   1.902


  1 in total

1.  Pharmacokinetics study of mazindol in plasma, oral fluid, and urine of volunteers.

Authors:  Marcella Herbstrith de Oliveira; Pâmela Cristina Lukasewicz Ferreira; Graciela Carlos; Fernanda Rodrigues Salazar; Ana Maria Bergold; Flavio Pechansky; Renata Pereira Limberger; Pedro Eduardo Fröehlich
Journal:  Eur J Clin Pharmacol       Date:  2016-04-12       Impact factor: 2.953

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.